Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Bcg

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Early Phase 1 (1)
Phase 2 (1)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT03748524Early Phase 1CompletedPrimary

Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine

NCT02560857CompletedPrimary

Clinical Evaluation of Quantiferon-Monitor to Predict Outcomes in Solid Organ Transplant Recipients

NCT00241657Phase 2CompletedPrimary

Immune Responses to BCG Vaccination in Malawi and the UK

Showing all 3 trials

Research Network

Common Treatments

  • Bcg1
  • Influenza Vaccine1
  • Quantiferonmonitor Assay1

Active Sponsors

  • Deepali Kumar1
  • Washington University School of Medicine1
  • London School of Hygiene and Tropical Medicine1

Top Investigators

Related Conditions

  • Hypersensitivity Delayed Type1

Activity Timeline